- Home
- DMAC vs GPRK Comparison
DMAC vs GPRK Comparison
Compare DMAC & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMAC | GPRK |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.6M | 608.0M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | DMAC | GPRK |
|---|---|---|
| Price | $6.58 | $9.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $15.50 | $8.50 |
| AVG Volume (30 Days) | 214.6K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.21% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | $39.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.34 | $5.75 |
| 52 Week High | $10.42 | $10.34 |
Technical Indicators
Market Signals| Indicator | DMAC | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 51.37 |
| Support Level | $6.56 | $7.96 |
| Resistance Level | $7.36 | $10.16 |
| Average True Range (ATR) | 0.48 | 0.57 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 50.00 | 55.10 |
Price Performance
Historical ComparisonAbout DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.